Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration

Meghan D. Morris, Stephen Shiboski, Julie Bruneau, Judith A. Hahn, Margaret Hellard, Maria Prins, Andrea L. Cox, Gregory Dore, Jason Grebely, Arthur Y. Kim, Georg M. Lauer, Andrew Lloyd, Thomas Rice, Naglaa Shoukry, Lisa Maher, Kimberly Page

Research output: Contribution to journalArticle

Abstract

Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated independent effects of city and calendar period on HCV infection risk. Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0). Incidence was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), lowest in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multivariable model. Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe programs in North America.

Original languageEnglish (US)
Pages (from-to)860-869
Number of pages10
JournalClinical Infectious Diseases
Volume64
Issue number7
DOIs
StatePublished - Apr 1 2017

Fingerprint

Hepacivirus
Incidence
Infection
Baltimore
Opioid Analgesics
Confidence Intervals
Needle Sharing
Syringes
Netherlands
Needles
Equipment and Supplies

Keywords

  • Epidemiology
  • Harm reduction strategies
  • Hepatitis C virus (HCV)
  • Incidence trends
  • People who inject drugs

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Morris, M. D., Shiboski, S., Bruneau, J., Hahn, J. A., Hellard, M., Prins, M., ... Page, K. (2017). Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration. Clinical Infectious Diseases, 64(7), 860-869. DOI: 10.1093/cid/ciw869

Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs : The InC3 collaboration. / Morris, Meghan D.; Shiboski, Stephen; Bruneau, Julie; Hahn, Judith A.; Hellard, Margaret; Prins, Maria; Cox, Andrea L.; Dore, Gregory; Grebely, Jason; Kim, Arthur Y.; Lauer, Georg M.; Lloyd, Andrew; Rice, Thomas; Shoukry, Naglaa; Maher, Lisa; Page, Kimberly.

In: Clinical Infectious Diseases, Vol. 64, No. 7, 01.04.2017, p. 860-869.

Research output: Contribution to journalArticle

Morris, MD, Shiboski, S, Bruneau, J, Hahn, JA, Hellard, M, Prins, M, Cox, AL, Dore, G, Grebely, J, Kim, AY, Lauer, GM, Lloyd, A, Rice, T, Shoukry, N, Maher, L & Page, K 2017, 'Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration' Clinical Infectious Diseases, vol 64, no. 7, pp. 860-869. DOI: 10.1093/cid/ciw869

Morris, Meghan D.; Shiboski, Stephen; Bruneau, Julie; Hahn, Judith A.; Hellard, Margaret; Prins, Maria; Cox, Andrea L.; Dore, Gregory; Grebely, Jason; Kim, Arthur Y.; Lauer, Georg M.; Lloyd, Andrew; Rice, Thomas; Shoukry, Naglaa; Maher, Lisa; Page, Kimberly / Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs : The InC3 collaboration.

In: Clinical Infectious Diseases, Vol. 64, No. 7, 01.04.2017, p. 860-869.

Research output: Contribution to journalArticle

@article{6e88e8462a1c4a8782c0bc239a9665ba,
title = "Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs: The InC3 collaboration",
abstract = "Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated independent effects of city and calendar period on HCV infection risk. Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0). Incidence was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), lowest in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multivariable model. Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe programs in North America.",
keywords = "Epidemiology, Harm reduction strategies, Hepatitis C virus (HCV), Incidence trends, People who inject drugs",
author = "Morris, {Meghan D.} and Stephen Shiboski and Julie Bruneau and Hahn, {Judith A.} and Margaret Hellard and Maria Prins and Cox, {Andrea L.} and Gregory Dore and Jason Grebely and Kim, {Arthur Y.} and Lauer, {Georg M.} and Andrew Lloyd and Thomas Rice and Naglaa Shoukry and Lisa Maher and Kimberly Page",
year = "2017",
month = "4",
doi = "10.1093/cid/ciw869",
volume = "64",
pages = "860--869",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Geographic differences in temporal incidence trends of hepatitis C virus infection among people who inject drugs

T2 - Clinical Infectious Diseases

AU - Morris,Meghan D.

AU - Shiboski,Stephen

AU - Bruneau,Julie

AU - Hahn,Judith A.

AU - Hellard,Margaret

AU - Prins,Maria

AU - Cox,Andrea L.

AU - Dore,Gregory

AU - Grebely,Jason

AU - Kim,Arthur Y.

AU - Lauer,Georg M.

AU - Lloyd,Andrew

AU - Rice,Thomas

AU - Shoukry,Naglaa

AU - Maher,Lisa

AU - Page,Kimberly

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated independent effects of city and calendar period on HCV infection risk. Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0). Incidence was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), lowest in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multivariable model. Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe programs in North America.

AB - Background. We determined temporal trends (1985-2011) in hepatitis C virus (HCV) incidence and associated behavioral exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), the Netherlands (Amsterdam), and Australia (Sydney and Melbourne). Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in exposure behaviors. Poisson regression models estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and estimated independent effects of city and calendar period on HCV infection risk. Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4-25.0). Incidence was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), lowest in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 [95% CI, .8-.9]) in the multivariable model. Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe programs in North America.

KW - Epidemiology

KW - Harm reduction strategies

KW - Hepatitis C virus (HCV)

KW - Incidence trends

KW - People who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=85018310244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018310244&partnerID=8YFLogxK

U2 - 10.1093/cid/ciw869

DO - 10.1093/cid/ciw869

M3 - Article

VL - 64

SP - 860

EP - 869

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -